Thomas John Betjeman

Thomas Betjeman practices at Presbyterian Hospital in Albuquerque, New Mexico, part of Presbyterian Healthcare Services.

Thomas Betjeman's NPI, 1164841565, was assigned on April 14, 2014. Thomas Betjeman holds New Mexico license MD2017-0422.

Thomas Betjeman's primary practice is Presbyterian Hospital, at 1100 Central Avenue SE, Albuquerque, NM 87106 in Bernalillo County. The practice phone is (505) 724-8386.

Thomas Betjeman's primary practice is Presbyterian Hospital in Albuquerque, New Mexico, part of Presbyterian Healthcare Services. Thomas Betjeman is also affiliated with Socorro General Hospital. The medical group on file is Presbyterian Medical Group. Dmand AI also links Thomas Betjeman to 3 more medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Thomas Betjeman practices, 3 sites in all. Vendor and product names are available with a free account.

Family medicine is Thomas Betjeman's primary specialty in the NPI Registry, under taxonomy code 207Q00000X. Dmand AI has Thomas Betjeman's licenses on file in 2 states: New Mexico and California.

CMS data shows 98 Medicare services from Thomas Betjeman across 4 procedure codes in 2024, for 92 Medicare patients. Medicare paid $9,832 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 92 Medicare patients who saw Thomas Betjeman in 2024. The largest group is 75 to 84, with 32 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 29% are also on Medicaid. Their average risk score is 1.59, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Thomas Betjeman's median patient age at 57, with 49% women.

In 2024, Thomas Betjeman wrote 159 Medicare Part D claims for 85 patients. 91% of them were for generic drugs. CMS names the drug for 24 of them, across 2 drugs with 11 or more claims each, at $236 in total drug cost. In 2023, CMS named 42 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Thomas Betjeman for performance year 2024, reported as part of a group. Thomas Betjeman accepts Medicare assignment, so Medicare's approved amount is taken as full payment.